Dr. Leffler will address a few commonly asked questions about celiac disease. He will discuss some common issues like diagnostic tests, the right implementation of the gluten free diet and who can benefit from such a diet.
In this activity, Dr. Damas will review the phenotypic manifestations and extra-intestinal manifestations of inflammatory bowel diseases, including Crohn’s and ulcerative colitis. She will explain what we currently know about disease pathogenesis, including the influence of genetics and the environment on the microbiome and finally, discuss some of the latest updates on treatment of IBD.
In this activity, Dr. Lee will discuss the advantages of early screening for gastric cancer. Using a case study as an example, she will review the pros and cons of available diagnostic tests. Finally, she will discuss premalignant condition such as gastric intestinal metaplasia and its association with gastric cancer.
IBS is a common gastrointestinal disorder characterized by chronic abdominal pain and an abnormal pattern of bowel movements (i.e., diarrhea, constipation or mixed diarrhea and constipation). This session will cover the diagnosis and management of this nebulous condition, including discussion of current guidelines and available and upcoming therapies for IBS.
This talk will outline the challenges associated with identifying patients with Barrett’s esophagus and the limitations of our current strategy of endoscopic surveillance biopsies. The risk of progression of nondysplastic Barrett’s esophagus, low-grade dysplasia, and high grade dysplasia to cancer will also be discussed. Endoscopic eradication techniques (EET) including endoscopic mucosal resection, radiofrequency ablation, and cryoablation will be described and the success rates and pros and cons of each type of EET will be reviewed.
This program aims to review evidence based recommendations for managing non-alcoholic fatty liver disease as well as understand indications for biopsy and further investigation.
Recent years have seen an increase in cases of severe and recurrent C. difficile induced diarrhea. Here, Dr. Gupta discusses risk factors predisposing patients to C. difficile infection and the approaches taken to manage such patient by focusing on five key strategies. She answers some common questions encountered while treating C. difficile infections including recommended antibiotic therapy and fecal microbiota transplant therapy.
Apply new guidelines for the diagnosis of these digestive disorders, and recommend dietary adjustments as indicated.
Dr. Gary Martin reviews some of the latest evidence on the use of colonoscopy, flexible sigmoidoscopy, and fecal testing for detecting colorectal cancer, and discusses the benefits and drawbacks of each.
The microbiome has been called the second human genome. It is shaped by how we were born, where we live and the foods and medicines we are given in childhood. In recent years, there has been an explosion in the number of scientific studies regarding the role of the gut microbiome in metabolic, allergic and autoimmune diseases. Therapeutic implications of altering the microbiome to alter disease states have taken shape and form an exciting new frontier of medicine.
In this activity will provide an overview of inflammatory bowel disease in children. Dr. Strople will review the pathogenesis of the disease and highlight the differentiating points between adult and pediatric IBD disease. Pathophysiology of crohn's disease and ulcerative colitis in children will also be discussed along with treatment and management strategies.
Nonalcoholic fatty liver (NAFL) is an emerging concern among a subset of the diabetic and obese population. Complications arise when the disease progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis. It is important for the primary care physician to recognize the hallmarks of NAFLD and the progression to NASH. Here, Dr. Chopra discusses strategies for diagnosis, treatment and management of patients with this hepatic disorder.